Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster III
Hematology Disease Topics & Pathways:
Technology and Procedures, Clinically relevant, Quality Improvement , NGS
Methods: Consecutive NGS orders were retrospectively collected from the molecular diagnostics laboratory and categorized as performed or cancelled up-front. The medical record for each patient was reviewed for specimen type, clinical indication, pathologic diagnosis, and molecular findings. These orders were categorized and analyzed according to our proposed criteria.
Results: AML/MDS NGS consecutive orders (n=139) performed from September to December 2018 identified 102 appropriately ordered tests and 12 orders that were carried through testing but would have been cancelled according to the proposed criteria. Four of these 12 (33%) tests identified pathogenic variants, compared with 71 of the 102 (70%) approved tests. These four inappropriately ordered tests included [a] 3 patients in whom there was no AML/MDS progression, prior known variants were re-identified, and no new variant was detected; and [b] 1 patient with a variant attributable to their non-myeloid neoplasm. The remaining 25 tests included 2 performed for a clinical trial and 23 that were cancelled up-front (22 appropriately) based on our proposed criteria. This suggests that approximately 25% (34/139, 24.5%) of AML/MDS NGS testing can be safely and appropriately cancelled using objective criteria. If the 12 tests had been cancelled up-front according to the criteria, approximately $9,360 could have been saved based on current Centers for Medicare and Medicaid Services (CMS) reimbursement. These results are summarized in Figure 1.
Discussion: Overall, the cancellation criteria excluded cases that were non-beneficial clinically. In the cases that had NGS performed but met our cancellation criteria, no significant variants were identified, supporting our recommendation. Additionally, the cost and time of reporting NGS studies is significant, and many laboratories can only perform a limited number of NGS tests per week. Thus, our criteria for performing or cancelling the AML/MDS NGS test may allow for more precise and cost-efficient myeloid neoplasm evaluations.
Disclosures: No relevant conflicts of interest to declare.
See more of: Oral and Poster Abstracts